5 results about "Camptothecin Analog" patented technology

Described herein are anti-NaPi2b antibody-drug conjugates (ADCs) comprising an antibody construct that binds to human sodium-dependent phosphate transporter 2B (NaPi2b) conjugated to a camptothecin analog of Formula (I). The antibody construct of the ADC comprises an amino acid modification in the Fc that knocks out binding to Fc gamma receptors. The ADCs are useful as therapeutic agents, among others, in the treatment of cancer.

The present disclosure relates to conjugates of camptothecin analogs of the formula T-(L-D) m with a cell binding molecule. The present disclosure also provides methods for preparing conjugates of camptothecin analogs with cell binding agents, and methods of using the conjugates in tumor-targeted therapy.

The present disclosure relates to conjugates of novel camptothecin analogs and cell-binding molecules of formula (I). Also provided are methods for preparing the conjugates of camptothecin analogs and cell-binding agents, and methods for applying the conjugates in targeted cancer therapy.

Provided are conjugates of camptothecin analogs with a cell-binding molecule of formula (I), wherein R1, R2, R3, R4, R5, X, L, n, m, T and ----- are defined herein. It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of using the conjugates in targeted treatment of cancer, infection, and immunological disorders.

The present invention provides antigen-binding proteins capable of binding to Nectin-4 polypeptides conjugated to chemotherapeutic agents for use in increasing the sensitivity of tumors to the chemotherapeutic agents for use in treating cancers characterized by Nectin-4-expressing tumor cells. In one embodiment, the present invention provides conjugates of anti-Nectin-4 antibodies conjugated to camptothecin analogs such as exatecan or SN-38 via a cleavable linker.